Clinical Trials Logo

Mycoses clinical trials

View clinical trials related to Mycoses.

Filter by:

NCT ID: NCT05357794 Recruiting - Mycosis Fungoides Clinical Trials

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

Start date: October 13, 2022
Phase: Phase 2
Study type: Interventional

To learn if a form of radiation therapy (called ultra-low-dose - total skin electron beam therapy [ULD-TSEBT]) in combination with brentuximab vedotin can help to control mycosis fungoides

NCT ID: NCT05336851 Recruiting - Sepsis Clinical Trials

Emergency PWAS in Respiratory Infectious Disease

Start date: April 11, 2023
Phase:
Study type: Observational [Patient Registry]

Develop an emergency PanorOmics Wide Association Study (ePWAS) for the early, rapid biological and pathophysiological characterisation of known and novel Infectious Diseases in adult patients presenting to emergency departments with suspected, acute, community-acquired respiratory infectious disease (scaRID). Phase 1 1. Develop an ED-ID biobank (named ePWAS-RID). Phase 2 2. Targeted research for the discovery of novel diagnostics, prognostics and therapeutics

NCT ID: NCT05235711 Recruiting - Fungal Infection Clinical Trials

The Role Of Interferon-gamma In Immune Responses To Invasive Candidiasis

Start date: February 10, 2022
Phase:
Study type: Observational

The purpose of the study is to investigate the role of the human immune response to candidemia/invasive candidiasis as it relates to the cytokine interferon-gamma.

NCT ID: NCT05202366 Recruiting - Onychomycosis Clinical Trials

An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal Infection

Start date: February 8, 2022
Phase:
Study type: Observational

The goal of the current study is to evaluate the ability of CGB-400, a proprietary eutectic mixture of GRAS compounds, to clear the toenail fungal growth and improve the appearance of the fungus affected area(s). This is an open-label, single group POC study evaluating the effectiveness of CGB-400 Topical Gel for toenail fungal growth clearing. The study consists of a 12-week period with 5 clinic visits at the following timepoints: Baseline (Day 0), and Weeks 2, 6, and 12 and post-application follow-up at Week 24. The applications could be extended for an additional 12 weeks based on PI's observations. Approximately 15 subjects will be enrolled and subjected to application of CGB-400 Topical Gel. Subjects must be at least 18 years of age and will be selected by the concerned PI.

NCT ID: NCT05153005 Recruiting - Clinical trials for Opportunistic Fungal Infections

Comprehensive Diagnosis and Treatment Strategy for Opportunistic Fungal Infections in AIDS Patients

Start date: April 1, 2021
Phase:
Study type: Observational

Opportunistic fungal infection is the most common opportunistic infection in AIDS patients, with the high mortality and recurrence rate due to the lack of standardized comprehensive diagnosis and treatment strategy. This project aims to combine traditional detection and observation indicators with molecular biology, serology and mass spectrometry identification technology to develop early screening and diagnostic strategies for opportunistic fungal infections in AIDS patients, explore scientific evaluation methods for anti-fungal efficacy and formulate comprehensive strategies for reducing the mortality and recurrence rate.

NCT ID: NCT05150327 Recruiting - Fungal Infection Clinical Trials

Multicenter Cohort Study of Invasive Fungal Filamentous Fungal Infections in Liver Transplant Patients

FongiFoie
Start date: November 1, 2021
Phase:
Study type: Observational

Invasive filamentous fungal infections (aspergillosis, scedosporiosis, mucormycosis, fusarium wilt) are frequent and serious in immunocompromised individuals and especially in organ transplant patients. There is little recent data in liver transplantation, especially on the incidence and risk factors of fungal infections

NCT ID: NCT05130723 Recruiting - Clinical trials for Invasive Fungal Infections

Pharmacokinetics of Fluconazole in Children (2-18 Years)

FOCUS
Start date: October 18, 2022
Phase:
Study type: Observational

30 pediatric patients aged 2-18 years receiving fluconazole as part of standard care for the treatment or prophylaxis of an invasive fungal infection will be included in the study. Between day 2 and 10, 6 samples will be collected on two days. In the case a patient switches from oral to intravenous therapy, an additional PK-day consisting of 3 samples will be scheduled. Fluconazole plasma concentrations will be determined. A pharmacokinetic model will be fitted to the data from all individuals simultaneously. Data will be analysed using non-linear mixed effects modelling (NONMEM). Monte Carlo simulations will guide the establishment of an improved fluconazole dosing regimen for pediatric and adolescent patients.

NCT ID: NCT05116059 Recruiting - Clinical trials for Invasive Fungal Disease

To Evaluate the Efficacy and Safety of ABCD in the Treatment of IFD

Start date: October 22, 2021
Phase:
Study type: Observational

In order to better guide clinical medication, verify the efficacy and safety of ABCD in the treatment of various invasive fungal disease, the investigators have designed a multi-center, retrospective registration study. Diagnosis and treatment data for patients with different types of invasive fungal disease in clinical actual environment was collapsed by a database for collaborative exchange on antifungal research.

NCT ID: NCT04961593 Recruiting - Pharmacokinetics Clinical Trials

PK/PD of Caspofungin in Children Severe Infection

Start date: October 1, 2022
Phase:
Study type: Observational

Caspofungin is an anti-fungal drug mainly metabolized by the liver. The pathophysiological status of children with severe infection will affect the metabolism of caspofungin in the body especially in the case of liver dysfunction. There is little metabolism of caspofungin through the kidney and continuous renal replacement therapy and renal function have little influence on the pharmacokinetics of caspofungin. The study aim to investigate PK/PD of caspofungin in children with specific pathophysiological conditions, such as liver insufficiency, hypoproteinemia, ECMO treatment, or sepsis.

NCT ID: NCT04960618 Recruiting - Mycosis Fungoides Clinical Trials

Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome

Start date: October 1, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out whether the combination of pembrolizumab and gemcitabine is an effective treatment for mycosis fungoides and Sézary syndrome.